Back to Search
Start Over
Immunoadsorption for connective tissue disease
- Source :
- Atherosclerosis Supplements. 14:185-189
- Publication Year :
- 2013
- Publisher :
- Elsevier BV, 2013.
-
Abstract
- Distinct connective tissue diseases (CTD's) such as systemic lupus erythematosus (SLE), systemic sclerosis, mixed connective tissue disease as well as dermato- and polymyositis comprise a group of diseases, where autoantibodies are not merely indicators of autoimmune disease, but also play an relevant role in the underlying pathogenicity. This knowledge led to the development of antibody targeting therapies using rituximab or belimumab. Upon this, therapeutic plasma exchange, and more recently immunoadsorption (IAS) have been successfully applied to remove pathogenic autoantibodies under various conditions in some of these CTD's. While the technique of IAS is superior to plasma exchange in regard to specificity and efficacy, the clinical use of IAS in CTD's is currently restricted to a small proportion of clinical situations with either refractory disease or the necessity to avoid aggressive immunosuppressive regimens. Despite the presence of a large number of case series and few controlled trials using IAS, there is a need for further prospective randomized trials to clearly define the role of IAS in these CTD's.
- Subjects :
- Autoimmunity
medicine.disease_cause
Scleroderma
Absorption
Mixed connective tissue disease
Internal Medicine
medicine
Humans
Connective Tissue Diseases
Immunoadsorption
Immunosorbent Techniques
Autoantibodies
Plasma Exchange
business.industry
Autoantibody
General Medicine
medicine.disease
Connective tissue disease
Belimumab
Treatment Outcome
Immunology
Blood Component Removal
Rituximab
Immunosorbents
Cardiology and Cardiovascular Medicine
business
Biomarkers
medicine.drug
Subjects
Details
- ISSN :
- 15675688
- Volume :
- 14
- Database :
- OpenAIRE
- Journal :
- Atherosclerosis Supplements
- Accession number :
- edsair.doi.dedup.....653106a245b2193f2196ca344a4846e0